Posted by Editor | Posted in Defective Drugs
Last week, super-sized drugmaker, Eli Lilly & Co., cleared problems with its top selling drug Zyprexa, an anti-psychotic medication, by paying out $62 million to 32 states and Washington, D.C.
Eli Lilly was charged with marketing the drug for off-label uses, such as pediatric care and treatment of dementia, and not properly disclosing the full range of side effects to healthcare providers.
The company didn’t acknowledge any wrongdoing. The settlement will be divided among the states based on population.
According to the Indiana attorney general, the company also agreed to appropriate its medical staff (not its marketing staff) with the responsibility for consenting to the content in “all medical letters and medical references regarding Zyprexa.”
“The one thing that’s really key here is they’ve agreed to have a much more transparent system,” the attorney general said.
Check out Total Injury’s related articles:
